Anthony Maina

Teva's expected loss of patent protection on its blockbuster drug Copaxone in 2014 could further hurt the company's already weak drug sales.

AmerisourceBergen is a great growth stock in an industry where growth is usually slow to moderate.

Pfizer does not face any major loss of patent protection on the drugs it manufactures, and remains a good investment.

JPMorgan's underlying strength will help it overcome the setbacks brought about by its huge legal settlements.

The current industry trend of falling smartphone prices and increasing competition in the 4G LTE space might eventually work out in Qualcomm's favor.

Intel's better brand recognition when compared to Qualcomm might soon prove decisive in the hotly-contested smart-devices chipset battle.

The criticism about Facebook's decision not to increase ad volumes is unwarranted. The social networking site will continue to thrive even with its relatively low ad volumes.

J.C. Penney is a good turnaround bet, and not a value trap as some investors seem to think.

TransDigm continues to shine in the aerospace industry.

CDW continues to shine even as the movement into the cloud gains momentum

Despite Outerwall's recent lowered revenue guidance and concerns about its DVD business, the company's still going strong and likely to continue growing in the near-term and even in the longer-term.

Although the shift by big companies into private health exchanges has impacted negatively on PBMs such as Express Scripts, leading players in the industry continue to do well.

Sears' bullish investors should consider the potential downside to the bullish Sears' real estate appraisal by Baker Street, and the fair value of the shares.

Amazon might face increasingly stiffer competition from firms in its own online retail space, as well as traditional brick-and-mortar stores.